What is the current Gamma-aminobutyric Acid (GABA) Receptor Agonist market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the GABA Receptor Agonist market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the GABA Receptor Agonist market?

Increasing demand for neurological treatments drives the market.

What challenges does the GABA Receptor Agonist market face?

Stringent regulatory approvals pose a challenge.

Which regions are the leaders in the GABA Receptor Agonist market?

North America and Europe are the leading regions.

Who are the top companies in the GABA Receptor Agonist market?

Pfizer and Merck are among the top companies.

What future opportunities exist in the GABA Receptor Agonist market?

Emerging economies offer growth opportunities.

How does technology impact the GABA Receptor Agonist market?

Advances in drug delivery technology enhance market growth.

What is the regulatory landscape for the GABA Receptor Agonist market?

Regulations vary by region, with FDA and EMA governing key markets.

What is the future outlook for the GABA Receptor Agonist market?

The market is expected to experience steady growth.

Gamma-aminobutyric Acid (GABA) Receptor Agonist - Strategic Insights: Analysis 2025 and Forecasts 2033

Gamma-aminobutyric Acid (GABA) Receptor Agonist by Type (/> Oral, Parenteral, Intrathecal, Others), by Application (/> Hospitals, Specialty Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Size | CAGR 8.2 Forecast 2033

Gamma-aminobutyric Acid (GABA) Receptor Agonist - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Overview

The Gamma-aminobutyric Acid (GABA) Receptor Agonist market is a crucial segment of the pharmaceutical industry, playing a significant role in the treatment of various neurological and psychological disorders. As the demand for effective treatments for anxiety, insomnia, and epilepsy continues to rise, the Gamma-aminobutyric Acid (GABA) Receptor Agonist market size is expected to witness substantial growth, driven by increasing research and development activities, advancements in technology, and a growing awareness of mental health. The growth outlook for the market is promising, with a projected market forecast of $1.4 billion by 2026, and an anticipated industry expansion at a CAGR of 8.5% during the forecast period from 2026 to 2033.

Loading chart…

The Gamma-aminobutyric Acid (GABA) Receptor Agonist market is primarily driven by factors such as technology shifts towards more targeted and effective treatments, regulations supporting the development of novel therapies, and changing consumer behavior towards mental health awareness. The largest region in the market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in healthcare infrastructure and a growing patient population. As the market continues to evolve, key players are focusing on developing innovative products and forming strategic partnerships to stay ahead of the competition.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.25 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Mylan N.V.; Teva Pharmaceutical Industries; Novartis; Aytu BioScience; Dr. Reddy’s Laboratories; Endo Pharmaceuticals; Lupin; Johnson & Johnson Services; Lannett; Sun Pharmaceutical Industries; Cipla; Aurobindo Pharma; Zydus Cadila
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gamma-aminobutyric Acid (GABA) Receptor Agonist market is poised for significant growth, driven by increasing demand for effective treatments of neurological and psychiatric disorders. The growth forecast for this market is promising, with the Gamma-aminobutyric Acid (GABA) Receptor Agonist market size expected to expand substantially over the next few years.

Growth Drivers2 items

Increasing prevalence of anxiety and insomnia disorders is driving the demand for Gamma-aminobutyric Acid (GABA) Receptor Agonist treatments, leading to a surge in the Gamma-aminobutyric Acid (GABA) Receptor Agonist market size

Advances in pharmaceutical technology are enabling the development of more effective and targeted GABA Receptor Agonist therapies, contributing to the growth forecast of the market

Restraints2 items

Stringent regulatory requirements and high research and development costs are limiting the entry of new players in the Gamma-aminobutyric Acid (GABA) Receptor Agonist market, thus affecting the growth forecast

Side effects associated with GABA Receptor Agonist treatments, such as drowsiness and dizziness, are hindering the adoption of these therapies and impacting the Gamma-aminobutyric Acid (GABA) Receptor Agonist market size

Opportunities2 items

Growing awareness about mental health and increasing demand for non-benzodiazepine treatments are creating new opportunities for Gamma-aminobutyric Acid (GABA) Receptor Agonist manufacturers, driving the growth forecast of the market

Emerging markets in Asia-Pacific and Latin America offer significant growth potential for GABA Receptor Agonist manufacturers, contributing to the expansion of the Gamma-aminobutyric Acid (GABA) Receptor Agonist market size

Challenges2 items

Intense competition among existing players in the Gamma-aminobutyric Acid (GABA) Receptor Agonist market is making it challenging for new entrants to gain market share and impacting the growth forecast

Fluctuations in raw material prices and supply chain disruptions are affecting the production costs and profitability of GABA Receptor Agonist manufacturers, thus influencing the Gamma-aminobutyric Acid (GABA) Receptor Agonist market size

Market Segmentation

Loading chart…

The Gamma-aminobutyric Acid (GABA) Receptor Agonist market can be segmented by type, which refers to the different classes of GABA receptor agonists, such as GABA_A receptor agonists and GABA_B receptor agonists. This segmentation is crucial in understanding the Gamma-aminobutyric Acid (GABA) Receptor Agonist segmentation market, as each type of agonist has distinct pharmacological properties and therapeutic applications. The type segmentation contributes to the overall market size by providing a framework for understanding the different mechanisms of action and potential therapeutic uses of GABA receptor agonists.

The application segmentation of the Gamma-aminobutyric Acid (GABA) Receptor Agonist market refers to the various therapeutic areas where these agonists are used, such as anxiety disorders, insomnia, and seizure disorders. This segmentation is essential in understanding the market taxonomy of GABA receptor agonists, as each application has unique market dynamics and competitive landscapes. The application segmentation contributes to the overall market size by providing insights into the different disease areas where GABA receptor agonists are used, and the potential opportunities and challenges in each area.

Gamma-aminobutyric Acid (GABA) Receptor Agonist Segmentation Breakdown9 items

Type

/> Oral

Parenteral

Intrathecal

Others

Application

/> Hospitals

Specialty Clinics

Others

Regional Insights

Loading chart…

The Gamma-aminobutyric Acid (GABA) Receptor Agonist market is poised for significant growth, with the Asia Pacific region emerging as the largest and fastest-growing market. Key drivers in North America include increased adoption of GABA receptor agonists in anxiety disorders, favorable policies supporting pharmaceutical research, and growing investments in neurological disorder treatments. In Europe, drivers include rising demand for mental health solutions, expanding infrastructure for clinical trials, and maturing ecosystem for pharmaceutical innovation.

In Asia Pacific, key drivers include growing demographics with increasing life expectancy, improving infrastructure for healthcare services, and government initiatives supporting pharmaceutical development. Latin America is driven by increasing awareness of mental health issues, growing investments in healthcare infrastructure, and expanding access to pharmaceutical treatments. The Middle East & Africa region is driven by growing demand for neurological disorder treatments, increasing adoption of GABA receptor agonists, and improving ecosystem for pharmaceutical research. The regional forecast indicates a significant Gamma-aminobutyric Acid (GABA) Receptor Agonist market growth in the coming years.

Competitive Landscape

The Gamma-aminobutyric Acid (GABA) Receptor Agonist competitive landscape is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, and product innovation. The market is driven by a combination of these levers, with companies seeking to differentiate themselves through certifications, regulatory approvals, and strategic partnerships. The Gamma-aminobutyric Acid (GABA) Receptor Agonist key players are focused on developing innovative products and expanding their distribution channels to maintain a competitive edge.

Companies in the market are adopting various strategies to stay competitive, including M&A, partnerships, product launches, and expansion into new regions. However, they face challenges such as margin pressure, compliance costs, and commoditization, which can erode their competitive advantage. To differentiate themselves, companies are focusing on technology, service models, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Sanofi: regional expansion

Mylan N.V.: vertical integration

Teva Pharmaceutical Industries: premium pricing

Novartis: innovation pipeline

Aytu BioScience: local manufacturing

Dr. Reddy’s Laboratories: OEM tie-ups

Key Gamma-aminobutyric Acid (GABA) Receptor Agonist Companies14 items

Sanofi

Mylan N.V.

Teva Pharmaceutical Industries

Novartis

Aytu BioScience

Dr. Reddy’s Laboratories

Endo Pharmaceuticals

Lupin

Johnson & Johnson Services

Lannett

Sun Pharmaceutical Industries

Cipla

Aurobindo Pharma

Zydus Cadila

Market Ecosystem

The Gamma-aminobutyric Acid (GABA) Receptor Agonist ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of GABA receptor agonist products, with various participants contributing to the overall value chain analysis.

Raw material suppliers — providing chemical components

OEMs/manufacturers — producing GABA receptor agonist products

Technology providers — developing novel formulations

System integrators/EPCs — ensuring product stability and efficacy

Distributors/channel partners — delivering products to end users

Regulators/standards bodies — overseeing safety and compliance

End users/buyers — driving demand for GABA receptor agonist products

In the Gamma-aminobutyric Acid (GABA) Receptor Agonist ecosystem, control points are primarily held by regulators and standards bodies, influencing adoption through safety and efficacy standards. Dependency risks arise from input constraints, such as raw material availability, and standards approvals. Switching costs and partnerships are also significant, as companies may need to adapt to changing regulatory requirements or form alliances to ensure product interoperability. The ecosystem's dynamics can differ by region, with varying regulatory frameworks and market demands impacting the flow of value through the ecosystem.

Recent Industry Insights

The Gamma-aminobutyric Acid (GABA) Receptor Agonist industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been several strategic partnerships, such as collaborations between pharmaceutical companies and research institutions, aimed at advancing the discovery of novel GABA receptor agonists. Furthermore, the industry has seen a surge in product launches, with companies introducing new therapies targeting various neurological and psychiatric disorders. Regulatory changes, including updates to clinical trial guidelines, have also impacted the landscape. Additionally, funding rounds and expansions have been secured by several key players, underscoring the growing interest in this therapeutic area.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Gamma-aminobutyric Acid (GABA) Receptor Agonist market. The market attractiveness is moderate, driven by the growing demand for treatments of neurological disorders. The competitive intensity is high, with key players competing for market share. The long-term outlook is positive, with the Gamma-aminobutyric Acid (GABA) Receptor Agonist market outlook expected to grow due to increasing research and development activities. The innovation landscape is evolving, with new products and technologies being introduced. However, the demand–supply balance is a concern, with potential shortages of raw materials. Key risk factors include regulatory changes and intense competition.

11 items

1. Executive Summary

2. Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Oral

6.1.2. Parenteral

6.1.3. Intrathecal

6.1.4. Others

6.2. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Specialty Clinics

6.2.3. Others

6.3. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Competition by Key Manufacturers

8.1. Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gamma-aminobutyric Acid (GABA) Receptor Agonist: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sanofi

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Mylan N.V.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Teva Pharmaceutical Industries

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Aytu BioScience

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dr. Reddy’s Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Endo Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Lupin

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Johnson & Johnson Services

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Lannett

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Sun Pharmaceutical Industries

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Cipla

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Aurobindo Pharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Zydus Cadila

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market

Figure 4: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Drivers

Figure 5: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Challenges

Figure 6: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Trends

Figure 7: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Opportunity

Figure 8: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Restraint

Figure 9: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Value (USD Million) By Region

Figure 15: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Value (USD Million) By Region

Figure 23: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Value (USD Million) By Region

Table 10: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sanofi Basic Information And Sales Area

Table 31: Sanofi. Products Portfolio

Table 32: Mylan N.V. Basic Information And Sales Area

Table 33: Mylan N.V.. Products Portfolio

Table 34: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 35: Teva Pharmaceutical Industries. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Aytu BioScience Basic Information And Sales Area

Table 39: Aytu BioScience. Products Portfolio

Table 40: Dr. Reddy’s Laboratories Basic Information And Sales Area

Table 41: Dr. Reddy’s Laboratories. Products Portfolio

Table 42: Endo Pharmaceuticals Basic Information And Sales Area

Table 43: Endo Pharmaceuticals. Products Portfolio

Table 44: Lupin Basic Information And Sales Area

Table 45: Lupin. Products Portfolio

Table 46: Johnson & Johnson Services Basic Information And Sales Area

Table 47: Johnson & Johnson Services. Products Portfolio

Table 48: Lannett Basic Information And Sales Area

Table 49: Lannett. Products Portfolio

Table 50: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 51: Sun Pharmaceutical Industries. Products Portfolio

Table 52: Cipla Basic Information And Sales Area

Table 53: Cipla. Products Portfolio

Table 54: Aurobindo Pharma Basic Information And Sales Area

Table 55: Aurobindo Pharma. Products Portfolio

Table 56: Zydus Cadila Basic Information And Sales Area

Table 57: Zydus Cadila. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Value (USD Million) By Region

Table 63: Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Type

Table 66: North America Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.25 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Mylan N.V.; Teva Pharmaceutical Industries; Novartis; Aytu BioScience; Dr. Reddy’s Laboratories; Endo Pharmaceuticals; Lupin; Johnson & Johnson Services; Lannett; Sun Pharmaceutical Industries; Cipla; Aurobindo Pharma; Zydus Cadila
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options